Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
AUTL Autolus Therapeutics	$2.65 +7.3%	$1.92	$1.11 ▼ $5.00	$705.27M	1.81	1.78 million shs	1.87 million shs
IPHA Innate Pharma	$1.70 -2.5%	$2.02	$1.29 ▼ $3.51	$156.71M	0.21	123,826 shs	5,697 shs
OTLK Oncobiologics	$2.32 +12.1%	$1.74	$0.87 ▼ $9.25	$77.88M	0.25	665,199 shs	1.23 million shs
SQZ SQZ Biotechnologies	$0.03	$0.03	$0.25 ▼ $3.56	$826K	2.34	455,220 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-91.97%
AUTL Autolus Therapeutics	0.00%	+4.22%	+16.51%	+84.33%	-41.88%
IPHA Innate Pharma	0.00%	-4.27%	-8.01%	-8.25%	-21.65%
OTLK Oncobiologics	0.00%	+14.36%	+13.74%	+48.92%	-76.42%
SQZ SQZ Biotechnologies	0.00%	0.00%	-6.67%	0.00%	-24.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1752 of 5 stars	3.8	0.0	0.0	0.0	0.6	0.0	0.0
AUTL Autolus Therapeutics	2.8672 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.6
IPHA Innate Pharma	2.6309 of 5 stars	3.8	3.0	0.0	0.0	2.7	1.7	0.0
OTLK Oncobiologics	2.5305 of 5 stars	3.4	4.0	0.0	0.0	2.8	0.0	0.6
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	251.70% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	547.06% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	313.79% Upside
SQZ SQZ Biotechnologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AUTL, SQZ, APTO, OTLK, and IPHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AUTL Autolus Therapeutics	$10.12M	69.69	N/A	N/A	$1.61 per share	1.65
IPHA Innate Pharma	$21.77M	7.20	N/A	N/A	$0.11 per share	15.45
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
SQZ SQZ Biotechnologies	$18.16M	0.05	N/A	N/A	$1.94 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)
SQZ SQZ Biotechnologies	-$79.46M	-$2.61	N/A	N/A	N/A	-369.96%	-119.83%	-59.90%	N/A

Latest AUTL, SQZ, APTO, OTLK, and IPHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
AUTL Autolus Therapeutics	N/A	9.24	9.02
IPHA Innate Pharma	2.52	2.60	2.60
OTLK Oncobiologics	N/A	0.72	0.57
SQZ SQZ Biotechnologies	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
AUTL Autolus Therapeutics	72.83%
IPHA Innate Pharma	0.16%
OTLK Oncobiologics	11.20%
SQZ SQZ Biotechnologies	38.51%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
AUTL Autolus Therapeutics	25.70%
IPHA Innate Pharma	31.89%
OTLK Oncobiologics	4.80%
SQZ SQZ Biotechnologies	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
SQZ SQZ Biotechnologies	1,620	29.49 million	24.77 million	Not Optionable

AUTL, SQZ, APTO, OTLK, and IPHA Headlines

Recent News About These Companies

SQZB SQZ Biotechnologies Company - Seeking Alpha

July 9, 2025 | seekingalpha.com

Serica Energy shares drop as Triton suspended until mid-March

February 18, 2025 | proactiveinvestors.co.uk

Serica Energy says 2025 outlook is â€˜promising'

January 21, 2025 | proactiveinvestors.co.uk

Serica Energy expects to remedy â€œclearly disappointingâ€ recent production performance

January 7, 2025 | proactiveinvestors.co.uk

SQZ Biotechnologies Co Ordinary Shares

December 23, 2024 | morningstar.comM

Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures

December 19, 2024 | finance.yahoo.com

Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight

September 5, 2024 | prnewswire.co.ukP

STEMCELL Launches Novel Cell-Engineering CellPore™ Transfection System

August 1, 2024 | valdostadailytimes.comV

What is the price tag to keep the biotech engine humming in Massachusetts?

July 23, 2024 | msn.com

SQZ Biotechnologies Company (SQZB)

May 22, 2024 | finance.yahoo.com

Sqz Bio (SQZB) Earnings Dates & Reports

May 8, 2024 | investing.com

VC funding update: who raised money in March?

April 1, 2024 | bizjournals.com

SQZ, Portal founder Armon Sharei on starting over in biotech

March 26, 2024 | biopharmadive.comB

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

March 19, 2024 | finance.yahoo.com

SQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to Stemcell

March 1, 2024 | fiercebiotech.comF

Rx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and more

February 16, 2024 | mmm-online.comM

SQZB SQZ Biotechnologies Company

December 28, 2023 | seekingalpha.com

SQZ Biotechnologies Co Ordinary Shares SQZB

December 12, 2023 | morningstar.comM

SQZ founder Armon Sharei opens Portal to to simplify intracellular delivery

December 12, 2023 | fiercebiotech.comF

'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site

November 11, 2023 | wral.comW

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SQZ, APTO, OTLK, and IPHA Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Autolus Therapeutics NASDAQ:AUTL

$2.65 +0.18 (+7.29%)

Closing price 04:00 PM Eastern

Extended Trading

$2.66 +0.00 (+0.19%)

As of 06:57 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Innate Pharma NASDAQ:IPHA

$1.70 -0.04 (-2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 +0.03 (+1.71%)

As of 05:50 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Oncobiologics NASDAQ:OTLK

$2.32 +0.25 (+12.08%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.86%)

As of 06:55 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

SQZ Biotechnologies NYSE:SQZ

$0.03 0.00 (0.00%)

As of 07/11/2025

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time